Repositorio Institucional de la Universidad de Oviedo

Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author:

Kudo, M.; Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Breder, V. V.; Varela Calvo, María; (et al.)

Publication date:

2024

Publisher version:

http://dx.doi.org/10.1016/j.annonc.2024.10.151

Descripción física:

p. S1451-S1452

URI:

https://hdl.handle.net/10651/78685

ISSN:

0923-7534; 1569-8041

DOI:

10.1016/j.annonc.2024.10.151

Patrocinado por:

AstraZeneca